TDOC Quote, Financials, Valuation and Earnings

Astrana Health has a net margin of -14.78% compared to Teladoc Health's net margin of 1.08%. Teladoc Health's return on equity of -61.6% beat Astrana Health's return on equity of 7.09%.

Teladoc Health has a consensus price target of $9.12, signalling upside risk potential of 15.72%. On the other hand Astrana Health has an analysts' consensus of $47.4444 which suggests that it could grow by 87.68%. Given that Astrana Health has higher upside potential than Teladoc Health, analysts believe Astrana Health is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.840, which suggesting that the stock is 83.977% more volatile than S&P 500. In comparison Astrana Health has a beta of 0.842, suggesting its less volatile than the S&P 500 by 15.811%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Astrana Health offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. Astrana Health pays out 9.35% of its earnings as a dividend. Astrana Health's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Teladoc Health quarterly revenues are $629.4M, which are larger than Astrana Health quarterly revenues of $620.4M. Teladoc Health's net income of -$93M is lower than Astrana Health's net income of $6.7M. Notably, Teladoc Health's price-to-earnings ratio is -- while Astrana Health's PE ratio is 35.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.53x versus 0.54x for Astrana Health. Usually stocks with elevated PS ratios are considered overvalued.

Biote has a net margin of -14.78% compared to Teladoc Health's net margin of 28%. Teladoc Health's return on equity of -61.6% beat Biote's return on equity of --.

Teladoc Health has a consensus price target of $9.12, signalling upside risk potential of 15.72%. On the other hand Biote has an analysts' consensus of $6.40 which suggests that it could grow by 56.05%. Given that Biote has higher upside potential than Teladoc Health, analysts believe Biote is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.840, which suggesting that the stock is 83.977% more volatile than S&P 500. In comparison Biote has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biote offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. Biote pays out 150.27% of its earnings as a dividend.

Teladoc Health quarterly revenues are $629.4M, which are larger than Biote quarterly revenues of $49M. Teladoc Health's net income of -$93M is lower than Biote's net income of $13.7M. Notably, Teladoc Health's price-to-earnings ratio is -- while Biote's PE ratio is 6.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.53x versus 0.72x for Biote. Usually stocks with elevated PS ratios are considered overvalued.

Cryo-Cell International has a net margin of -14.78% compared to Teladoc Health's net margin of 4.49%. Teladoc Health's return on equity of -61.6% beat Cryo-Cell International's return on equity of --.

Teladoc Health has a consensus price target of $9.12, signalling upside risk potential of 15.72%. On the other hand Cryo-Cell International has an analysts' consensus of $8.50 which suggests that it could grow by 73.12%. Given that Cryo-Cell International has higher upside potential than Teladoc Health, analysts believe Cryo-Cell International is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.840, which suggesting that the stock is 83.977% more volatile than S&P 500. In comparison Cryo-Cell International has a beta of 0.659, suggesting its less volatile than the S&P 500 by 34.131%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cryo-Cell International offers a yield of 13.24% to investors and pays a quarterly dividend of $0.15 per share. Teladoc Health pays -- of its earnings as a dividend. Cryo-Cell International pays out 502.5% of its earnings as a dividend.

Teladoc Health quarterly revenues are $629.4M, which are larger than Cryo-Cell International quarterly revenues of $7.9M. Teladoc Health's net income of -$93M is lower than Cryo-Cell International's net income of $355.8K. Notably, Teladoc Health's price-to-earnings ratio is -- while Cryo-Cell International's PE ratio is 498.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.53x versus 1.27x for Cryo-Cell International. Usually stocks with elevated PS ratios are considered overvalued.

P3 Health Partners has a net margin of -14.78% compared to Teladoc Health's net margin of -5.49%. Teladoc Health's return on equity of -61.6% beat P3 Health Partners's return on equity of -53.56%.

Teladoc Health has a consensus price target of $9.12, signalling upside risk potential of 15.72%. On the other hand P3 Health Partners has an analysts' consensus of $8.00 which suggests that it could grow by 23.08%. Given that P3 Health Partners has higher upside potential than Teladoc Health, analysts believe P3 Health Partners is more attractive than Teladoc Health.

Teladoc Health has a beta of 1.840, which suggesting that the stock is 83.977% more volatile than S&P 500. In comparison P3 Health Partners has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Teladoc Health has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. P3 Health Partners offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Teladoc Health pays -- of its earnings as a dividend. P3 Health Partners pays out -- of its earnings as a dividend.

Teladoc Health quarterly revenues are $629.4M, which are larger than P3 Health Partners quarterly revenues of $373.2M. Teladoc Health's net income of -$93M is lower than P3 Health Partners's net income of -$20.5M. Notably, Teladoc Health's price-to-earnings ratio is -- while P3 Health Partners's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Teladoc Health is 0.53x versus 0.01x for P3 Health Partners. Usually stocks with elevated PS ratios are considered overvalued.